Originally published In Press as doi:10.1074/jbc.M201389200 on March 14, 2002
J. Biol. Chem., Vol. 277, Issue 21, 18568-18573, May 24, 2002
Identification of Amino Acids Important for the Catalytic
Activity of the Collagen Glucosyltransferase Associated with the
Multifunctional Lysyl Hydroxylase 3 (LH3)*
Chunguang
Wang,
Maija
Risteli,
Jari
Heikkinen,
Anna-Kaisa
Hussa,
Lahja
Uitto, and
Raili
Myllylä
From the Department of Biochemistry, Biocenter Oulu, University of
Oulu, P. O. Box 3000, University of Oulu, FIN-90014,
Finland
Received for publication, February 11, 2002, and in revised form, March 12, 2002
 |
ABSTRACT |
Collagen glucosyltransferase (GGT) activity has
recently been shown to be associated with human lysyl hydroxylase (LH)
isoform 3 (LH3) (Heikkinen, J., Risteli, M., Wang, C., Latvala, J.,
Rossi, M., Valtavaara, M., Myllylä, R. (2000) J. Biol. Chem. 275, 36158-36163). The LH and GGT activities of the
multifunctional LH3 protein modify lysyl residues in collagens
posttranslationally to form hydroxylysyl and glucosylgalactosyl
hydroxylysyl residues respectively. We now report that in the nematode,
Caenorhabditis elegans, where only one ortholog is found
for lysyl hydroxylase, the LH and GGT activities are also associated
with the same gene product. The aim of the present studies is the
identification of amino acids important for the catalytic activity of
GGT. Our data indicate that the GGT active site is separate from the
carboxyl-terminal LH active site of human LH3, the amino acids
important for the GGT activity being located at the amino-terminal part
of the molecule. Site-directed mutagenesis of a conserved cysteine at
position 144 to isoleucine and a leucine at position 208 to isoleucine caused a marked reduction in GGT activity. These amino acids were conserved in C. elegans LH and mammalian LH3, but not in
LH1 or LH2, which lack GGT activity. The data also reveal a
DXD-like motif in LH3 characteristic of many
glycosyltransferases and the mutagenesis of aspartates of this motif
eliminated the GGT activity. Reduction in GGT activity was not
accompanied by a change in the LH activity of the molecule. Thus GGT
activity can be manipulated independently of LH activity in LH3. These
data provide the information needed to design knock-out studies for
investigation of the function of glucosylgalactosyl hydroxylysyl
residues of collagens in vivo.
 |
INTRODUCTION |
Glycosylation is a posttranslational modification important for
the function of many proteins in vivo. For example, it is required for processes mediated by specific protein-carbohydrate interactions, such as protein targeting, cell adhesion, cell motility, protein dimerization, etc. (1). Mice carrying deletions in genes for
glycosyltransferases have been described, some deletions leading to
embryonic or perinatal lethality, whereas others are not essential for
development and survival (1, 2).
Collagens are a large family of glycoproteins, which are ubiquitously
distributed in almost all tissues of the body. It is known that
collagens are structural building blocks of tissues and, in addition,
have regulatory functions important for cell behavior. The biosynthesis
of collagen is a multistep process including many posttranslational
modifications, some of which are unique to collagens (3-6). These
include the hydroxylation of lysyl residues and glycosylation of
hydroxylysyl residues. The sugars linked to hydroxylysyl residues are
galactose or a disaccharide glucosylgalactose and are present only in
collagens and proteins having collagenous amino acid sequence in
their structure (3-6).
The number of hydroxylysyl and glycosylated hydroxylysyl residues
varies among different collagen types. The numbers may also vary in the
same collagen type in different tissues and in different physiological
states (3-6). Studies on bone collagen, for instance, indicate that
the lysyl modifications vary among different skeletal regions according
to the main function the bone exerts in different locations (7).
Hydroxylysyl residues play an important role in collagen cross-link
formation, hydroxylysyl derived cross-links being typically found in
skeletal and major internal connective tissues (3, 6, 8). Many of the
cross-links are glycosylated (9). Recent studies have demonstrated
changes in the cross-link profile in osteoporosis, a disease with a
decrease in bone strength (8). There is evidence that hydroxylation of
lysyl residues in collagen is associated with mineralization of
fibrils, a high hydroxylation level preventing the deposit of minerals
between the fibrils (10). Furthermore, studies on fibrillar collagens have indicated that an increased content of glycosylated hydroxylysyl residues of collagen is associated with a decrease of fibril diameter both in vivo and in vitro (11, 12). The detailed
biological functions of galactosylhydroxylysyl and
glucosylgalactosylhydroxylysyl residues are not known, however. There
are no studies so far using transgenic animals to study the
consequences of abnormalities of the glycosylated hydroxylysyl residues
in vivo, and there is no information regarding possible
heritable disorders caused by defects in these modifications.
Lysyl hydroxylase (LH, EC
1.14.11.4)1 in the mouse and
human is present in three different molecules, LH1, LH2, and LH3, originating from three different genes (16-21). Galactosylhydroxylysyl glucosyltransferase (GGT, EC 2.4.1.66) catalyzes a transfer of the
glucose from UDP-glucose to galactosylhydroxylysyl residues in the
presence of Mn2+ (3-6, 13). We recently found (14) that
GGT activity is associated with the lysyl hydroxylase 3 (LH3) gene
product. Accordingly, the first and last of three consecutive steps in
the synthesis of hydroxylysine-linked carbohydrates in collagens are
catalyzed by the same enzyme.
The ability to selectively delete or alter predetermined genes in an
animal model provides enormous power for the study of gene function.
The deletion of the mouse or human LH3 gene, for instance, will lead to
a disturbance of the consecutive steps in hydroxylysine-linked
carbohydrate formation. To investigate the specific function of
glucosylation, however, the selective inhibition of the GGT activity of
LH3 is required. To prepare for these studies, more information about
the amino acids of LH3 responsible for the GGT activity is needed. In
this study we have investigated the catalytic properties of the single
ortholog of lysyl hydroxylase found in the nematode
Caenorhabditis elegans (22) and found that LH and GGT
activities are associated with the same gene product. We have
characterized amino acids important for GGT activity in human LH3 and
C. elegans LH and shown that these amino acids are
localized at the amino-terminal part of the molecule, separate from the
lysyl hydroxylase active site. This enables us to manipulate the gene
to remove the GGT activity without affecting the LH activity of the
gene product.
 |
EXPERIMENTAL PROCEDURES |
Cell Cultures--
Sf9 (Spodoptera frugiperda)
insect cells were grown in Sf-900 II serum-free medium
(Invitrogen). Escherichia coli XL1-Blue cells
transformed with different LH constructs were grown in LB broth
containing 100 µg/ml ampicillin.
Expression of cDNAs in Insect Cells--
Baculovirus
transfer vector pFastBac1 in the BAC-TO-BACTM (Invitrogen)
expression system was used in the production of recombinant proteins.
The LH3 construct (18) expressed in insect cells produced a recombinant
protein having a signal peptide from the human LH1 sequence, a His tag
at the amino terminus after signal peptide cleavage, and the amino
acids encoded by nucleotides 289-2455 of the LH3 cDNA sequence.
The insect cells were harvested 72 h after infection and
homogenized as described earlier (18).
Expression of cDNAs in Bacterial Cells--
The LH3 cDNA
construct used in this study was described elsewhere (14). The insert
for the C. elegans LH (corresponding to amino acids
14-730 in the cDNA) was generated by PCR (Dr. Robert Barstead
kindly provided us with a C. elegans cDNA library)
and ligated into the E. coli SacI-PstI
site of a pQE30 vector. The recombinant proteins have the whole coding
sequence without the signal sequence and a His tag at the amino
terminus. Constructs were transformed into the E. coli
XL1-Blue strain and cultures were grown to an OD600 of
0.6-0.7 at 37 °C. Proteins were induced by the addition of 1 mM isopropyl-1-thio-
-D-galactopyranoside at
30 °C for 5 h. For activity measurements, the cells were
resuspended in lysis buffer (0.4 M NaCl, 0.5% Nonidet P-40, and 20 mM Tris-HCl, pH 7.8, at 20 °C) and incubated in the
presence of lysozyme (50 µg/ml) and RNase A (10 µg/ml) at room
temperature for 30 min. Lysis was completed by sonication. The cell
debris was removed by centrifugation and the supernatant was used in
the measurements. For the protein mobility shift assay, 10 mM iodoacetamide was used in the lysis buffer to alkylate
the proteins.
Enzyme Activity Assays--
LH activity was assayed by a method
based on the hydroxylation-coupled decarboxylation of
2-oxo[1-14C]glutarate (23) with the synthetic peptide
IKGIKGIKG as a substrate. GGT activities were measured by a method
based on the transfer of radioactively (tritium) labeled glucose from
UDP-sugar to galactosylhydroxylysyl residues in a calf skin gelatin
substrate (24). The specific detection of the reaction products was
performed after alkaline hydrolysis.
Other Assays--
In vitro translation was carried
out as described elsewhere (14) by using a pCITE 4a vector (Novagen)
for the transcription and a STP3 kit (Novagen) for the translation.
Western blot analysis was carried out using monoclonal antibodies
against the His tag (Sigma). The proteins were fractionated under
reducing or non-reducing conditions by 10% SDS-PAGE, blotted onto an
Immobilon-P membrane (Millipore), and incubated with the primary
antibody. Anti-mouse IgG peroxidase conjugate (Zymed
Laboratories Inc.) was used as the secondary antibody. Bound
antibodies were visualized using the ECL detection system (Amersham
Biosciences) and x-ray film (Eastman Kodak Co). The QuikChange
site-directed mutagenesis kit (Stratagene) was used to make mutations
in the cDNA sequences. The nucleotide changes of the mutations were
confirmed by sequencing.
 |
RESULTS AND DISCUSSION |
GGT Activity in E. coli Cells Transformed with the C. elegans Lysyl
Hydroxylase cDNA Construct--
The whole genome of C. elegans has been recently sequenced (15), and the sequence data
indicate that there is a single gene for lysyl hydroxylase (22). To
express the protein in E. coli and to determine whether the
LH gene product possesses the GGT activity, which has been found to be
associated with human LH3 (14), we have prepared a cDNA construct
for C. elegans LH. Control E. coli cells,
containing only the pQE30 vector, as well as cells expressing DHFR,
have only very low residual GGT activity (<300 dpm/mg soluble cell
protein). When the C. elegans LH cDNA was expressed in
E. coli cells, GGT activity was present in the soluble protein fraction. Due to different expression levels, the activity varied in different experiments, giving values in the range of 21,000 up to 30,700 dpm/mg soluble protein.
Amino Acids Conserved in LH3 and C. elegans--
Our data indicate
that GGT activity is associated with the LH of C. elegans and LH3 of human (14) and
mouse,2 whereas human LH1 and
LH2 possess only LH activity (14). To determine the conserved amino
acids for the multifunctional GGT/LH protein (Fig.
1) we have aligned the C. elegans LH and mouse and human LH3 cDNA sequences and compared
them to the sequences of LH1 (bovine, rat, chicken, mouse, human) and
LH2 (mouse, human). There are 29 amino acids conserved between the LH3
sequences and C. elegans sequence (LH3-C.
elegans-specific amino acids) but differing from the LH1 and LH2
sequences (shaded black, Fig. 1). The amino acids are
scattered evenly throughout the molecule. The whole
Drosophila genome has also recently been sequenced (25), and
only one gene was found for LH in this genome. As seen in Fig. 1, 11 of
the 29 amino acids are conserved also in the Drosophila lysyl hydroxylase.

View larger version (87K):
[in this window]
[in a new window]
|
Fig. 1.
Alignment of lysyl hydroxylase isoform
sequences of bovine, rat, chicken, human, mouse, C. elegans, and Drosophila.
Bovine (GenBankTM accession no. AF054274),
rat (GenBankTM accession no. L25331), and
chicken (GenBankTM accession no. M59183)
sequences most probably represent the LH1 isoform of lysyl hydroxylase.
Only one isoform for lysyl hydroxylase is found in the genomes of
C. elegans (15) (GenBankTM accession no. Z66512)
and Drosophila (24) (GenBankTM accession no.
AE003545). The amino acids conserved between the LH3
sequences (mouse, GenBankTM accession no. AF
046783; human, AF046889) and the C. elegans
sequence but differing from LH1 (mouse,
GenBankTM accession no. AF046782; human, L06419)
and LH2 (mouse, GenBankTM accession
no. AF080572; human, U84573) sequences are shaded
black, whereas DXD-like motifs in these molecules
are shaded gray.
|
|
LH3-C. elegans-specific Amino Acids Necessary for GGT
Activity--
In vitro mutagenesis combined with an
in vitro translation system was used in our experiments
(Fig. 2). Both C. elegans and human LH3 sequence were used in the studies. We
started to search the important amino acids for GGT activity with
C. elegans LH. The most inhibitory changes and
one as a control of carboxyl-terminal area were tested further with
human LH3. Aspartic acid at position 392 in human LH3 conserved in all
species of LH isoforms was mutated to alanine as it was one candidate
of the DXD motif of the molecule (see later). The data was
then confirmed in an E. coli system for the human LH3 (not
shown). We mutated the LH3-C. elegans-specific amino acids
to the amino acids present in LH1 and/or LH2. As seen in Fig. 2,
mutations at the amino-terminal end of the molecule caused an
inhibition of GGT activity, whereas mutations at the carboxyl-terminal
end of the molecule had no effect on this activity. Two mutations, the
C144I and L208I in the human sequence and the C132I and L196I in
the C. elegans sequence, inhibited GGT activity markedly in
both species suggesting that these amino acids, conserved in
LH3-C.elegans LH, are important for the catalytic activity of GGT. Our data also reveal some differences in the GGT active sites
between C. elegans and human. Two leucine changes,
L124V and L125V, in the C. elegans sequence inhibited the
GGT activity by 40 and 70%, whereas the corresponding mutations in the
human sequence increased GGT activity. Furthermore, a mutation of A453I in the C. elegans sequence (corresponding to
Ala464 of the human LH3 sequence) caused a remarkable
inhibition of GGT activity, whereas the corresponding change in the
human sequence had no effect on this activity.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 2.
The effect of mutation of LH3-C.
elegans-specific amino acids on GGT activity. C. elegans LH and human LH3 were expressed by an in vitro
translation system. The translation level was analyzed by SDS-PAGE and
autoradiography (not shown). The activity without any mutation is taken
as 100.
|
|
During in vitro mutagenesis studies we also generated a
C. elegans molecule, in which Leu124
(C. elegans sequence) was mutated to valine, and
the molecule also contained a tandem duplication of 11 amino acids
(His-Tyr-Ser-Glu-Lys-Arg-Val-Leu-Phe-Gly-Ala) in the amino-terminal
region. This change reduced the GGT activity dramatically when compared
with a single amino acid change in the molecule, giving a GGT activity
value of 0.5% (not shown). These data suggest that disruption of the
structure of the molecule by the insertion of amino acids at this
position abolishes the GGT activity.
There is no data about the multifunctionality of the LH gene in
Drosophila, but it is interesting to note that the
conservated amino acids, Cys144 and Leu208 in
the human sequence, are also found in the Drosophila LH,
suggesting a possible association of GGT activity with the insect LH
gene. It is worth noting that the amino acid corresponding to
Ala464 of the human sequence (Ala453 in
C. elegans sequence) is isoleucine in the
Drosophila sequence, which corresponds to the LH1 sequence
in this position.
Cys144 Forming a Disulfide Bond in LH3
Structure?--
We used the alkylating agent, iodoacetamide, to block
free sulfhydryl groups to determine whether the human
Cys144 forms a disulfide bond in the LH3 molecule (26).
E. coli cells producing His-tagged LH3 were lysed in the
presence of the alkylating reagent, and the proteins purified on a
nickel column were then analyzed under non-reduced and reduced
condition by SDS-PAGE combined with Western blotting. As seen in Fig.
3, under non-reducing conditions LH3
migrates as a monomer. There is a shift in the electrophoretic mobility
after reduction of the native LH3 by DTT, suggesting the presence of
disulfide bonds in the native molecule (Fig. 3). The molecule in which
Cys144 was mutated to isoleucine behaved like the native
molecule in the gel, suggesting that Cys144 is
not-disulfide linked in contrast to Cys494 and
Cys577, which seem to be disulfide-bonded in human LH3
(Fig. 3). Cys494 and Cys577 are conserved in
all lysyl hydroxylase isoforms (Fig. 1). We measured GGT activity in
alkylated and non-alkylated LH3 samples by using both crude cell
supernatant and nickel column-purified enzyme preparations in our
assay. The data indicate no decrease in the activity in the alkylated
samples (not shown). As already indicated above (Fig. 2), mutation of
Cys144 to Ile reduced GGT activity dramatically.
Accordingly, our data suggest that the Cys144 is required
for the functional integrity of GGT but does not form a disulfide link
and probably does not participate directly in the enzyme catalysis.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 3.
The effect of DTT on the mobility of human
recombinant LH3 and Cys mutants. The E. coli cells
producing His-tagged LH3 were lysed in lysis buffer (see
"Experimental Procedures") in the presence of 10 mM
iodoacetamide. The LH3 was purified with a nickel column and treated
with or without 125 mM DTT before separation by 10%
SDS-PAGE. The mobility of LH3 was recognized on the Western blots by a
His tag antibody. Lanes 1 and 2: LH3 without
mutation. Lanes 3 and 4: LH3 with
Cys144 mutated to Ile. Lanes 5 and 6:
LH3 with Cys494 mutated to Ser. Lanes 7 and
8: LH3 with Cys577 mutated to Ser.
The presence and absence of DTT is indicated.
|
|
The Amino Acid Changes Inhibiting Glucosyltransferase Activity Do
Not Affect LH Activity--
The baculovirus expression system was used
to determine whether amino acid changes that inhibited the GGT activity
of LH3 have an effect on the LH activity. We studied the most effective mutations of human LH3, i.e. C144I and L208I, in an LH activity assay.
Our results (data not shown) indicate for GGT that the results
were independent on the expression system used for the recombinant
protein production, the baculovirus, and in vitro translation, and that the E. coli system gave similar values
for the mutated molecule. Our data for LH indicates that these
mutations did not have any effect on LH activity, however. This is
consistent with our earlier data obtained from LH1, that the amino
acids responsible for LH activity are located in the carboxyl-terminal portion of the molecule (27, 28). The carboxyl-terminal part of
the molecule is the most conserved region among the LH isoforms (16-20).
The Amino-terminal Part of LH3 Is Able to Generate GGT
Activity--
Our data above suggest that the amino-terminal portion
of the LH3 molecule is important for GGT activity. To determine whether the carboxyl-terminal portion of the molecule is required for GGT
activity, we removed amino acids from the carboxyl-terminal end of the
human LH3. We generated a translational stop codon in different parts
of the molecule, and the truncated LH3 molecules produced in E. coli and insect cells (baculovirus system) were assayed for GGT
activity (Fig. 4). These data indicate
that shortening the carboxyl-terminal portion of the LH3 molecule
reduces, but does not eliminate, GGT activity. A 355-amino acid-long
portion of amino-terminal moiety is still able to generate a low GGT
activity (Fig. 4). None of the truncated molecules were able to
hydroxylate lysyl residues (not shown), confirming our previous finding
that amino acids important for lysyl hydroxylase activity are located on the carboxyl-terminal portion of the molecule (27, 28).

View larger version (6K):
[in this window]
[in a new window]
|
Fig. 4.
GGT activity of truncated human LH3. The
activity values are obtained in cells producing recombinant LH3, in
E. coli, and baculovirus (insect cell) systems. The activity
values are corrected to the expression level of recombinant protein.
LH3, LH3 covering the amino acids from 33 (without a signal
sequence) up to 738 without any mutation (18, 19). M2,
M7, and M5, the molecule having a
translational stop codon after amino acid 520, 401, and 388, respectively. The activity value of M2 in insect cells has been
reported earlier (14).
|
|
A DXD Motif Required for GGT Activity--
Sequence alignments and
x-ray crystal structures have revealed a so-called DXD motif
in many glycosyltransferases, and this motif has been found in
different glycosyltransferase families (29). The motif is thought to
stabilize the Mn2+ and thus indirectly stabilize the
binding of the diphosphate moiety of the UDP-sugar (29, 30). Therefore
we looked for this motif in GGT. There are at least three
DXD-like motifs in the LH3 sequence (Fig. 1). Our data from
the first screenings, a point mutation of DAD to AAD (Figs. 1 and 2)
indicate that the DXD-like motif at position 392-394 of
human sequence is not important for GGT. Our data from the shortened
molecules (see above) show that the amino-terminal portion of the
molecule retains some of the GGT activity, suggesting that
DXD-like sequence at the carboxyl-terminal portion of the
molecules (at position 489-491) were not essential for the activity. A
short conserved motif containing many aspartate residues is located in
the sequence at position 187-191 (Fig. 1), and mutation of aspartates
in this sequence eliminated the GGT activity (Fig.
5). This suggests that this short region
is important for catalytic activity and might be a Mn2+
binding site in GGT. The crystal structure of the catalytic domain of
GGT is required to prove the suggestion, however.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 5.
DXD-like motif in LH3
required for GGT activity. Human LH3 was expressed in an E. coli system. Aspartates in the sequence, amino acids 187-191 (18,
19) were selectively mutated to alanine, and the GGT activity was
measured. The expression level of recombinant protein was analyzed by
His tag antibodies on Western blot as shown in the figure.
|
|
Could GGT Activity Be Restored in LH1, LH2a, and/or LH2b by
Mutating Amino Acids to the LH3-C. elegans-specific Amino
Acids?--
Mutation analyses were used to determine whether LH1
and/or LH2 (LH2a and LH2b) would possess GGT activity if some of the LH3-C. elegans-specific amino acids were introduced into their structure. Six amino acid changes were analyzed: Ile to Cys in LH1 and
Leu to Cys in LH2a/LH2b (corresponding to the change C144I or C144L
between LH3 and LH1/LH2, see Fig. 1), and Ile to Leu (corresponding to
the change L208I between LH3 and LH1/LH2a/LH2b, see Fig. 1) in LH1 and
LH2. We also generated molecules where both changes were introduced in
the same molecule. The mutated proteins were expressed in E. coli, and GGT activity was measured. However, the activity
measurements revealed no GGT activity (not shown). This data suggest
that LH1 and LH2 have diverged during evolution from the ancestral LH
and LH3 (20) such that replacement of the two most conserved amino
acids into their structures is not sufficient to restore GGT activity.
As observed in our data, there are evolutionary changes also between
LH3 and C. elegans sequence; the active sites are not
identical in these species although GGT activity is present in both molecules.
Conclusions--
We report in this paper amino acids important for
collagen glucosyltransferase activity, the glycosyltransferase
associated with unique hydroxylysine-linked glycosylation of collagens.
The activity has recently been found to be associated with a single human gene product (14), which is also a lysyl hydroxylase isoform (18,
19). In the human LH3 sequence, Cys144, which is probably
not disulfide-linked, and Leu208 are important for GGT
activity. These amino acids are also found in the C. elegans
LH gene product, which possesses GGT activity. The corresponding amino
acids in LH1 and LH2a/LH2b are isoleucine, and neither isoform has GGT
activity. Mutation of the cysteine to isoleucine and the leucine to
isoleucine in LH3 reduces GGT activity dramatically. These conserved
amino acids are not responsible for the LH activity of LH3, suggesting
that the LH and GGT active sites are separated on the LH3 molecule. The
distinct locations of the active sites of LH and GGT on the LH3
molecule were also demonstrated by truncation of the LH3 molecule,
which removed the LH active site. The truncated molecules still
retained some GGT activity. Our data furthermore reveal a
DXD-like sequence, a motif characteristic of many
glycosyltransferases, required for GGT activity in the multifunctional
LH molecule.
The results of this study are highly significant. We have identified
amino acids important for GGT activity, which provide tools to
manipulate this activity of the LH3 molecule. This knowledge is
essential for the design of knock-out and transgenic studies to
elucidate the functions of the glucosylation of galactosylhydroxylysyl residues in vivo. These experiments may also provide
information about possible heritable disorders associated with abnormal
glucosylation of galactosylhydroxylysyl residues in
vivo.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Robert Barstead for
providing the C. elegans library. We gratefully acknowledge
Anna-Maija Koisti for expert technical assistance.
 |
FOOTNOTES |
*
This work was supported by grants from the Research Council
for Biosciences and Environment within the Academy of Finland, a grant
from the Sigrid Juselius Foundation, and a grant from the Biocenter
Oulu.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 358-8-5531160;
Fax: 358-8-5531141; E-mail: raili.myllyla@oulu.fi.
Published, JBC Papers in Press, March 14, 2002, DOI 10.1074/jbc.M201389200
2
L. Sipilä, J. Heikkinen, and
R. Myllylä, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
LH, lysyl
hydroxylase;
GGT, galactosylhydroxylysyl glucosyltransferase;
DTT, dithiothreitol.
 |
REFERENCES |
| 1.
|
Dennis, W. J.,
Granovsky, M.,
and Warren, C. E.
(1999)
BioEssays
21,
412-421[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Vollrath, B.,
Fitzgerald, K. J.,
and Leder, P.
(2001)
Mol. Cell. Biol.
21,
5688-5697[Abstract/Free Full Text]
|
| 3.
|
Kielty, C. M.,
Hopkinson, I.,
and Grant, M. E.
(1993)
in
Connective Tissue and Its Heritable Disorders
(Royce, P. M.
, and Steinmann, P. M., eds)
, pp. 103-147, Wiley-Liss, New York
|
| 4.
|
Kadler, K.
(1994)
Protein Profile
1,
525-534, 545-549
|
| 5.
|
Prockop, D. J.,
and Kivirikko, K. I.
(1995)
Annu. Rev. Biochem.
64,
403-434[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Bateman, J. F.,
Lamande, S. R.,
and Ramshaw, J. A. M.
(1996)
in
Extracellular Matrix
(Comp er, W. D., ed)
, pp. 22-67, Harwood Academic Publishers, Amsterdam, The Netherlands
|
| 7.
|
Moro, L.,
Romanello, M.,
Favia, A.,
Lamanna, M. P.,
and Lozupone, E.
(2000)
Calcif. Tissue Int.
66,
151-156[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Knott, L.,
and Bailey, A. J.
(1998)
Bone
22,
181-187[Medline]
[Order article via Infotrieve]
|
| 9.
|
Ayad, S.,
Boot-Handford, R.,
Humphries, M. J.,
Kadler, K. E.,
and Shuttleworth, C. A.
(1998)
The Extracellular Matrix Facts Book
, pp. 43-125, Academic Press, London
|
| 10.
|
Wassen, M. H. M.,
Lammens, J.,
Tekoppele, J. M.,
Sakkers, R. J. B.,
Liu, Z.,
Verbaut, A. J.,
and Bank, R. A.
(2000)
J. Bone Miner. Res.
15,
1776-1785[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Brinckmann, J.,
Notbohm, H.,
Tronnier, M.,
Acil, Y.,
Fietzek, P. P.,
Schmeller, W.,
Müller, P. K.,
and Batge, B.
(1999)
J. Invest. Dermatol.
113,
617-621[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Notbohm, H.,
Nokelainen, M.,
Myllyharju, J.,
Fietzek, P. P.,
and Kivirikko, K. I.
(1999)
J. Biol. Chem.
274,
8988-8992[Abstract/Free Full Text]
|
| 13.
|
Kivirikko, K. I.,
and Myllylä, R.
(1979)
Int. Rev. Connect. Tissue Res.
8,
23-72[Medline]
[Order article via Infotrieve]
|
| 14.
|
Heikkinen, J.,
Risteli, M.,
Wang, C.,
Latvala, J.,
Rossi, M.,
Valtavaara, M.,
and Myllylä, R.
(2000)
J. Biol. Chem.
275,
36158-36163[Abstract/Free Full Text]
|
| 15.
|
Wixon, J.,
Blaxter, M.,
Hope, I.,
Barstead, R.,
and Kim, S.
(2000)
Yeast
17,
37-42[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Hautala, T.,
Byers, M. G.,
Eddy, R. L.,
Shows, T. B.,
Kivirikko, K. I.,
and Myllylä, R.
(1992)
Genomics
13,
62-69[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Valtavaara, M.,
Papponen, H.,
Pirttilä, A. M.,
Hiltunen, K.,
Helander, H.,
and Myllylä, R.
(1997)
J. Biol. Chem.
272,
6831-6834[Abstract/Free Full Text]
|
| 18.
|
Valtavaara, M.,
Szpirer, C.,
Szpirer, J.,
and Myllylä, R.
(1998)
J. Biol. Chem.
273,
12881-12886[Abstract/Free Full Text]
|
| 19.
|
Passoja, K.,
Rautavuoma, K.,
Ala-Kokko, L.,
Kosonen, T.,
and Kivirikko, K. I.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
10482-10486[Abstract/Free Full Text]
|
| 20.
|
Ruotsalainen, H.,
Sipilä, L.,
Kerkelä, E.,
Pospiech, H.,
and Myllylä, R.
(1999)
Matrix Biol.
18,
325-329[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Sipilä, L.,
Szatanik, M.,
Vainionpää, H.,
Ruotsalainen, H.,
Myllylä, R.,
and Guenet, J.-L.
(2000)
Mamm. Genome
11,
1132-1134[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Norman, K. R.,
and Moerman, D. G.
(2000)
Dev. Biol.
227,
690-705[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Kivirikko, K. I.,
and Myllylä, R.
(1982)
Methods Enzymol.
82,
245-304[Medline]
[Order article via Infotrieve]
|
| 24.
|
Myllylä, R.,
Risteli, L.,
and Kivirikko, K. I.
(1975)
Eur. J. Biochem.
52,
401-410[Medline]
[Order article via Infotrieve]
|
| 25.
|
Adams, M. D.,
Celniker, S. E.,
Holt, R. A.,
et al..
(2000)
Science
24,
2185-2195
|
| 26.
|
Braakman, I.,
Helenius, J.,
and Helenius, A.
(1992)
EMBO J.
11,
1717-1722[Medline]
[Order article via Infotrieve]
|
| 27.
|
Pirskanen, A.,
Kaimio, A. M.,
Myllylä, R.,
and Kivirikko, K. I.
(1996)
J. Biol. Chem.
271,
9398-9402[Abstract/Free Full Text]
|
| 28.
|
Passoja, K.,
Myllyharju, J.,
Pirskanen, A.,
and Kivirikko, K. I.
(1998)
FEBS Lett.
434,
145-148[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Ünligil, U. M.,
Zhou, S.,
Yuwaraj, S.,
Sarkar, M.,
Schacter, H.,
and Rini, J. M.
(2000)
EMBO J.
19,
5269-5280[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Gastinel, L. N.,
Bignon, C.,
Misra, A.,
Hindsgaul, O.,
Shaper, J. H.,
and Joziasse, D. H.
(2001)
EMBO J.
20,
638-649[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. Sipila, H. Ruotsalainen, R. Sormunen, N. L. Baker, S. R. Lamande, M. Vapola, C. Wang, Y. Sado, A. Aszodi, and R. Myllyla
Secretion and Assembly of Type IV and VI Collagens Depend on Glycosylation of Hydroxylysines
J. Biol. Chem.,
November 16, 2007;
282(46):
33381 - 33388.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Ruotsalainen, L. Sipila, M. Vapola, R. Sormunen, A. M. Salo, L. Uitto, D. K. Mercer, S. P. Robins, M. Risteli, A. Aszodi, et al.
Glycosylation catalyzed by lysyl hydroxylase 3 is essential for basement membranes
J. Cell Sci.,
February 15, 2006;
119(4):
625 - 635.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Risteli, O. Niemitalo, H. Lankinen, A. H. Juffer, and R. Myllyla
Characterization of Collagenous Peptides Bound to Lysyl Hydroxylase Isoforms
J. Biol. Chem.,
September 3, 2004;
279(36):
37535 - 37543.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.